Pharma Sector Q4 Earnings Preview - Domestic Markets To Boost Growth: KRChoksey
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
KRChoksey Research Report
Pharma companies are expected to continue their strong performance in Q4 FY21, after recovering from Covid-19 driven disruptions in previous quarters.
Recovery in chronic and acute therapies, higher demand for Covid-19 therapy products due to resurgence of Covid cases since February 2021 will be drivers for domestic business while increased ramp up in existing markets and products, as well as new product launches will be the drivers for international markets.
For Q4 FY21, we expect our coverage universe to post 10.2% YoY growth in sales.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.